Prognostic impact of pleural effusion in <i>EGFR</i>‐mutant non‐small cell lung cancer patients without brain metastasis

Yoshimura, Akihiro; Yamada, Tadaaki; Tsuji, Taisuke; Hamashima, Ryosuke; Shiotsu, Shinsuke; Yuba, Tatsuya; Takumi, Chieko; Uchino, Junichi; Hiraoka, Noriya; Takayama, K.

doi:10.1111/1759-7714.12979

Cited by 8 publications

(4 citation statements)

References 34 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung adenocarcinoma patients who harbor the exon 19 deletion are known to present with better survival than patients with the exon 21 L858R mutation [31,32]. Patients with liver and pleural metastases had worse survival outcomes, which agrees with the outcomes of previous studies [33][34][35].…”

Section: Discussionsupporting

confidence: 88%

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Chang

Huang

et al. 2022

Cancers

View full text Add to dashboard Cite

The aim of this retrospective study was to investigate the tolerability and survival outcomes of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment in patients with a performance status ≥ 2. The data for 517 patients treated with EGFR-TKIs between January 2011 and January 2018 at a regional hospital in northern Taiwan were analyzed. Clinical and pathological features were collected, and univariate as well as multivariable analyses were undertaken to identify potential prognostic factors. The overall objective response rate, median progression-free survival (PFS), and median overall survival (OS) were 56.3%, 11.4 months, and 15.3 months, respectively. The mutation status (exon 19 deletion), locally advanced disease, dose adjustment, and the lack of liver and pleural metastasis were independent and favorable prognostic factors for PFS. Age < 60 years, mutation status (exon 19 deletion), dose adjustment, and lack of lung, liver, and no pleural metastasis were independent and favorable prognostic factors for OS. GFR-TKIs demonstrated acceptable efficacy and safety in the current cohort. Dose adjustment was identified as an independent prognostic factor for both PFS and OS, regardless of which EGFR-TKIs were used. The current research provided novel evidence of the clinical prescription of frontline EGFR-TKIs for EGFR-mutated lung adenocarcinoma patients with a PS score ≥2.

show abstract

Section: Discussionsupporting

confidence: 88%

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Chang

Huang

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…TM7SF2 has been shown to be associated with T/NK cells in normal lymph nodes [ 103 ]. ZDHHC9 has been shown to be associated with myeloid cells in pleural effusion [ 108 ]. GNG12 and ITGA2 have been reported to relate to T/NK cells in pleural effusion [ 109 ].…”

Section: Discussionmentioning

confidence: 99%

Identifying Lung Cancer Cell Markers with Machine Learning Methods and Single-Cell RNA-Seq Data

Huang

Zhang

Lei

et al. 2021

Life

View full text Add to dashboard Cite

Non-small cell lung cancer is a major lethal subtype of epithelial lung cancer, with high morbidity and mortality. The single-cell sequencing technique plays a key role in exploring the pathogenesis of non-small cell lung cancer. We proposed a computational method for distinguishing cell subtypes from the different pathological regions of non-small cell lung cancer on the basis of transcriptomic profiles, including a group of qualitative classification criteria (biomarkers) and various rules. The random forest classifier reached a Matthew’s correlation coefficient (MCC) of 0.922 by using 720 features, and the decision tree reached an MCC of 0.786 by using 1880 features. The obtained biomarkers and rules were analyzed in the end of this study.

show abstract

“…Brain metastases (BM) are the most common central nervous system tumors with significant morbidity and poor survival outcomes [1] . A recent study found that up to 50 percent of patients with advanced non-small-cell lung cancer (NSCLC) develop BM, which is a significant reason for mortality [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Preoperative neutrophil-to-lymphocyte ratio (preNLR) for the assessment of tumor characteristics in lung adenocarcinoma patients with brain metastasis

Cui

Yang

Feng

et al. 2022

Translational Oncology

View full text Add to dashboard Cite

Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis

Cited by 8 publications

References 34 publications

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Identifying Lung Cancer Cell Markers with Machine Learning Methods and Single-Cell RNA-Seq Data

Preoperative neutrophil-to-lymphocyte ratio (preNLR) for the assessment of tumor characteristics in lung adenocarcinoma patients with brain metastasis

Contact Info

Product

Resources

About